Annora's Generic Eplerenone Receives Approval in the U.S.
Kartha's Generic Eplerenone Receives Approval in the U.S.
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, today announced a collaboration with Bristol Myers Squibb on a clinical trial of a combination therapy using RGX-104 (abequolixron), the Company’s small molecule agonist of the Liver X Receptor/Apolipoprotein E (“LXR/APOE”) pathway, and Yervoy® (ipilimumab), Bristol Myers Squibb’s Cytotoxic T-Lymphocyte Associated protein 4 (CTLA-4) inhibitor. Under the terms of the agreement, Bristol Myers Squibb will provide ipilimumab for a Phase 1b/2 expansion study investigating the combination therapy for the 2nd and 3rd line treatment of patients with metastatic endometrial cancer whose genomes possess the E2 or E4 APOE genetic biomarker, including those patients who have progressed on prior checkpoint inhibitor therapy. Inspirna will sponsor the study and be responsible for study costs.
June 2021 Price Concessions 1st Update
WASHINGTON (Reuters) - The U.S. Federal Trade Commission said on Friday that it had approved generic drugmaker Mylan NV's MYL.O planned purchase of Pfizer's PFE.N Upjohn, subject to conditions.
Piramal Healthcare `s Generic Eplerenone Receives Approval in US
Breckenridge Pharm's Generic Eplerenone Receives Approval in US
Accord’s Generic Eplerenone Receives Approval In US
Mylan's Generic Eplerenone Receives Approval In US
Bayer announced Monday that by year's end it will expand the clinical development programme for its novel non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone, also known as BAY 94-8862, with three Phase III studies in patients with chronic heart failure and patients with diabetic kidney disease.